XML 27 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows provided by (used in) operating activities      
Net income (loss) $ 2,960,532 $ 3,620,127 $ (1,159,816)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities      
Amortization, accretion and depreciation 258,456 (134,753) (26,950)
Equity in undistributed (earnings) losses of other ventures 9,035 (7,642) 10,723
Net realized and unrealized (gains) losses on investments (29,439) (482,794) 1,635,192
Change in:      
Premiums receivable (9,546) (126,852) (1,357,929)
Prepaid reinsurance premiums 36,445 223,385 (166,690)
Reinsurance recoverable 862,896 663,909 (442,256)
Deferred acquisition costs and value of business acquired 199,078 37,301 (322,578)
Reserve for claims and claim expenses 816,622 (34,656) 2,597,943
Unearned premiums (185,720) (227,001) 1,027,894
Reinsurance balances payable (381,830) (1,040,110) 67,318
Other (371,707) (579,280) (259,168)
Net cash provided by (used in) operating activities 4,164,822 1,911,634 1,603,683
Cash flows provided by (used in) investing activities      
Proceeds from sales and maturities of fixed maturity investments trading 23,515,450 21,796,577 22,086,168
Purchases of fixed maturity investments trading (26,296,842) (24,771,411) (24,923,131)
Proceeds from sales of equity investments 463 566,040 659,199
Purchases of equity investments (205) (1,715) (861,508)
Proceeds from sales of short term investments 31,772,072 41,152,880 26,612,585
Purchases of short term investments (31,597,588) (39,309,700) (25,972,174)
Proceeds from sales of other investments 1,087,445 489,658 408,944
Purchases of other investments (1,525,665) (1,291,508) (1,027,734)
Proceeds from sales of investments in other ventures 0 0 3,545
Purchases of investments in other ventures (57,335) (25,265) (4,318)
Return of investments in other ventures 41,349 5,554 2,248
Net purchase of Validus 0 (2,433,746) 0
Net cash provided by (used in) investing activities (3,060,856) (3,822,636) (3,016,176)
Cash flows provided by (used in) financing activities      
Dividends paid – RenaissanceRe common shares (80,849) (75,112) (64,675)
Dividends paid – preference shares (35,375) (35,375) (35,396)
RenaissanceRe common share repurchases (666,921) 0 (166,664)
RenaissanceRe common share issuance, net of expenses 0 1,351,608 0
Issuance of debt, net of expenses 0 740,581 0
Repayment of Medici Revolving Credit Facility (150,000) (30,000) 0
Drawdown of Medici Revolving Credit Facility 75,000 75,000 0
Subscriptions of third-party redeemable noncontrolling interest shares 537,433 982,914 1,277,945
Redemptions of third-party redeemable noncontrolling interest shares (943,223) (400,458) (274,957)
Taxes paid on withholding shares (23,580) (20,518) (10,911)
Net cash provided by (used in) financing activities (1,287,515) 2,588,639 725,342
Effect of exchange rate changes on foreign currency cash (17,365) 5,542 22,471
Net increase (decrease) in cash and cash equivalents (200,914) 683,179 (664,680)
Cash and cash equivalents, beginning of year 1,877,518 1,194,339 1,859,019
Cash and cash equivalents, end of year 1,676,604 1,877,518 1,194,339
Supplemental disclosure of cash flow information      
Income taxes paid (refunded) 99,535 26,777 3,129
Interest paid 88,046 73,543 46,247
Non-cash consideration [1] $ 0 $ 285,168 $ 0
[1] Represents the non-cash component of the total Validus Acquisition consideration. Refer to “Note 3. Acquisition of Validus” for additional information related to the Validus Acquisition.